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Purpose of the study
Darunavir is one of the protease inhibitors that is
recommended to treat protease inhibitor-naïve or
-experienced patients. Recent studies have determined
the spectrum of darunavir activity in patients failing to
antiretroviral therapy. Darunavir resistance mutations in
protease gene have been identified (V11I, V32I, L33F,
I47V, I50V, I54L, I54M, T74P, L76V, I84V and L89V)
and allow to classify viruses as sensitive (<3 mutations),
possibly resistant (3 mutations) or resistant (≥4m u t a -
tions) to darunavir.
Methods
1583 genotypic resistance tests performed between 2008
and 2009 for darunavir-naïve patients experiencing viro-
logical failure (whatever the antireroviral combination
used) were analyzed retrospectively. Protease gene was
sequenced and aminoacid changes analyzed at time of
virological failure. The number of darunavir resistance
mutations were determined and the strains were classi-
fied regarding the spectrum of darunavir activity (ANRS
algorithm V18).
Summary of results
Among these experienced patients failing antiretroviral
therapy, 63% harbored no darunavir mutations in the
protease gene and 12%, 16%, 4% and 5% harbored 1, 2,
3 and at least 4 darunavir mutations, respectively.
Patients with viruses harboring darunavir mutations had
lower HIV-1 viral load than patients with viruses with-
out any darunavir mutations.
Conclusions
This study shows that the percentage of genotypic fully
resistant strains to darunavir is rare in a population of
darunavir-naïve patients experiencing virological failure.
A large proportion of patients harbored viruses without
any darunavir resistance mutations allowing the use of
darunavir/r (800/100 mg) QD. Virological failures with-
out selection of any mutations showed higher viral load
level rebound probably related to lack of adherence.
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